Zydus Lifesciences gets USFDA nod for generic medication
Zydus Lifesciences on Monday said it has received approval from the US health regulator to market a generic medication that is used to lower triglycerides, in the American market. The company has got the final approval from USFDA to market Icosapent Ethyl Capsules in strength of 0.5 g and 1 g.
Zydus Lifesciences on Monday said it has received approval from the US health regulator to market a generic medication that is used to lower triglycerides, in the American market. The company has got the final approval from the US Food and Drug Administration (USFDA) to market Icosapent Ethyl Capsules in strength of 0.5 g and 1 g, it said in a regulatory filing.
The capsules are indicated as an adjunct to diet to reduce triglyceride levels in adult patients with severe hypertriglyceridemia.
Also Read: Samsung likely headed for first quarterly loss in 15 years: Analysts
As per IQVIA data, Icosapent Ethyl Capsules, 0.5 g and 1 g, had annual sales of USD 1,316 million in the US.
Shares of the company were trading marginally higher at Rs 518.80 apiece on BSE.
Catch latest stock market updates here. For all other news related to business, politics, tech, sports and auto, visit Zeebiz.com.
Get Latest Business News, Stock Market Updates and Videos; Check your tax outgo through Income Tax Calculator and save money through our Personal Finance coverage. Check Business Breaking News Live on Zee Business Twitter and Facebook. Subscribe on YouTube.